These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 15793188)

  • 1. Metabolic syndrome and risk of restenosis in patients undergoing percutaneous coronary intervention.
    Rana JS; Monraats PS; Zwinderman AH; de Maat MP; Kastelein JJ; Doevendans PA; de Winter RJ; Tio RA; Frants RR; van der Laarse A; van der Wall EE; Jukema JW;
    Diabetes Care; 2005 Apr; 28(4):873-7. PubMed ID: 15793188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinases 2 and 3 gene polymorphisms and the risk of target vessel revascularization after percutaneous coronary intervention: Is there still room for determining genetic variation of MMPs for assessment of an increased risk of restenosis?
    Verschuren JJ; Sampietro ML; Pons D; Trompet S; Ewing MM; Quax PH; de Knijff P; Zwinderman AH; de Winter RJ; Tio RA; de Maat MP; Doevendans PA; Jukema JW
    Dis Markers; 2010; 29(5):265-73. PubMed ID: 21206012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic background determines the importance of NOS3 polymorphisms in restenosis after percutaneous coronary intervention: A study in patients with and without the metabolic syndrome.
    Pons D; Monraats PS; Zwinderman AH; de Maat MP; Doevendans PA; de Winter RJ; Tio RA; Waltenberger J; Jukema JW
    Dis Markers; 2009; 26(2):75-83. PubMed ID: 19407362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of metabolic syndrome on in-stent restenosis and clinical outcomes after percutaneous coronary stent implantation.
    Kim JS; Lee HC; Choi BK; Lee HW; Park JS; Lee YH; Ahn MS; Hong TJ; Kim SP; Lee SK; Kim YD
    Diabetes Res Clin Pract; 2010 Jun; 88(3):e38-41. PubMed ID: 20427098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gender differences in patients treated with the zotarolimus-eluting stent at a tertiary medical center.
    Shammas NW; Shammas GA; Lemke J; Miller S; Meriner S
    J Invasive Cardiol; 2012 Jun; 24(6):256-60. PubMed ID: 22684377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome of patients undergoing low aggressive angioplasty combined with brachytherapy and short-term dual antiplatelet therapy for in-stent restenosis.
    Di Pede F; Buja P; Millosevich P; Grassi G; Celestre M; Zuin G; Marchetti C; Pizzi G; Antonello M; Bindoni L; Raviele A
    J Cardiovasc Med (Hagerstown); 2006 Oct; 7(10):731-6. PubMed ID: 17001233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of established genetic variation in the haemostatic system on clinical restenosis after percutaneous coronary interventions.
    Pons D; Monraats PS; de Maat MP; Pires NM; Quax PH; van Vlijmen BJ; Rosendaal FR; Zwinderman AH; Doevendans PA; Waltenberger J; de Winter RJ; Tio RA; Frants RR; van der Laarse A; van der Wall EE; Jukema JW
    Thromb Haemost; 2007 Dec; 98(6):1323-8. PubMed ID: 18064331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting the restenosis benefit of drug-eluting versus bare metal stents in percutaneous coronary intervention.
    Yeh RW; Normand SL; Wolf RE; Jones PG; Ho KK; Cohen DJ; Cutlip DE; Mauri L; Kugelmass AD; Amin AP; Spertus JA
    Circulation; 2011 Oct; 124(14):1557-64. PubMed ID: 21900079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Provisional stenting for multivessel PCI.
    Han B; Liu L; Aboud M; Nahir M; Hasin Y
    Int J Cardiovasc Intervent; 2005; 7(1):46-51. PubMed ID: 16019615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of restenosis and disease progression on clinical outcome after multivessel stenting in diabetic patients.
    Loutfi M; Mulvihill NT; Boccalatte M; Farah B; Fajadet J; Marco J
    Catheter Cardiovasc Interv; 2003 Apr; 58(4):451-4. PubMed ID: 12652493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nine-month outcome of patients treated by percutaneous coronary interventions for bifurcation lesions in the recent era: a report from the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial.
    Garot P; Lefèvre T; Savage M; Louvard Y; Bamlet WR; Willerson JT; Morice MC; Holmes DR
    J Am Coll Cardiol; 2005 Aug; 46(4):606-12. PubMed ID: 16098423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the effect of oral verapamil on clinical outcome and angiographic restenosis after percutaneous coronary intervention: the randomized, double-blind, placebo-controlled, multicenter Verapamil Slow-Release for Prevention of Cardiovascular Events After Angioplasty (VESPA) Trial.
    Bestehorn HP; Neumann FJ; Büttner HJ; Betz P; Stürzenhofecker P; von Hodenberg E; Verdun A; Levai L; Monassier JP; Roskamm H
    J Am Coll Cardiol; 2004 Jun; 43(12):2160-5. PubMed ID: 15193674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors for ischemic target vessel revascularization in the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial.
    Singh M; Gersh BJ; McClelland RL; Ho KK; Willerson JT; Penny WF; Holmes DR
    J Am Coll Cardiol; 2005 Jan; 45(2):198-203. PubMed ID: 15653015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events and restenosis in patients undergoing coronary stent implantation: a prospective study.
    Akcakoyun M; Kargin R; Tanalp AC; Pala S; Ozveren O; Akcay M; Barutcu I; Kirma C
    Coron Artery Dis; 2008 Aug; 19(5):337-43. PubMed ID: 18607171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes after bare-metal stenting in diabetic patients with lesions carrying a low risk of restenosis.
    Woudstra P; Damman P; Beijk MA; Grundeken MJ; Harskamp RE; Koch KT; Henriques JP; Baan J; Vis MM; Piek JJ; Tijssen JG; de Winter RJ
    Catheter Cardiovasc Interv; 2013 Jan; 81(1):26-33. PubMed ID: 22511590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors and impact of target vessel revascularization after stent implantation for acute ST-segment elevation myocardial infarction: lessons from HORIZONS-AMI.
    Brener SJ; Ertelt K; Mehran R; Genereux P; Xu K; Witzenbichler B; Brodie BR; Guagliumi G; Stone GW
    Am Heart J; 2015 Feb; 169(2):242-8. PubMed ID: 25641533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. -455G/A polymorphism and preprocedural plasma levels of fibrinogen show no association with the risk of clinical restenosis in patients with coronary stent placement.
    Monraats PS; Rana JS; Zwinderman AH; de Maat MP; Kastelein JP; Agema WR; Doevendans PA; de Winter RJ; Tio RA; Waltenberger J; Frants RR; van der Laarse A; van der Wall EE; Jukema JW
    Thromb Haemost; 2005 Mar; 93(3):564-9. PubMed ID: 15735811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired flow-mediated dilation and risk of restenosis in patients undergoing coronary stent implantation.
    Patti G; Pasceri V; Melfi R; Goffredo C; Chello M; D'Ambrosio A; Montesanti R; Di Sciascio G
    Circulation; 2005 Jan; 111(1):70-5. PubMed ID: 15630038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study.
    Cortese B; Micheli A; Picchi A; Coppolaro A; Bandinelli L; Severi S; Limbruno U
    Heart; 2010 Aug; 96(16):1291-6. PubMed ID: 20659948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracoronary beta brachytherapy as a treatment option for high-risk refractory in-stent restenosis; Compassionate use.
    Kim S; Almeda FQ; Tessalee M; Snell RJ; Nathan S; Thew S; Nguyen C; Chu JC; Schaer GL
    Cardiovasc Radiat Med; 2004; 5(1):9-14. PubMed ID: 15275626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.